| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pregnancy | 74 | 2021 | 815 | 4.240 |
Why?
|
| Pregnancy Complications | 15 | 2018 | 80 | 3.330 |
Why?
|
| Oxytocics | 6 | 2017 | 11 | 2.420 |
Why?
|
| Labor, Induced | 8 | 2018 | 10 | 2.340 |
Why?
|
| Postpartum Hemorrhage | 12 | 2020 | 14 | 2.200 |
Why?
|
| Cesarean Section | 16 | 2020 | 82 | 2.160 |
Why?
|
| Oxytocin | 7 | 2017 | 22 | 2.060 |
Why?
|
| Receptors, Oxytocin | 4 | 2017 | 8 | 2.010 |
Why?
|
| Delivery, Obstetric | 13 | 2020 | 50 | 1.830 |
Why?
|
| Pregnancy Outcome | 14 | 2018 | 52 | 1.820 |
Why?
|
| Female | 85 | 2021 | 18173 | 1.740 |
Why?
|
| Uterine Contraction | 4 | 2016 | 7 | 1.620 |
Why?
|
| Adult | 52 | 2021 | 8426 | 1.580 |
Why?
|
| Uterus | 4 | 2016 | 73 | 1.550 |
Why?
|
| Pre-Eclampsia | 6 | 2020 | 53 | 1.530 |
Why?
|
| Obstetric Labor Complications | 5 | 2017 | 12 | 1.520 |
Why?
|
| Chorioamnionitis | 5 | 2018 | 8 | 1.290 |
Why?
|
| Humans | 83 | 2021 | 29123 | 1.290 |
Why?
|
| Magnesium Sulfate | 2 | 2018 | 6 | 1.250 |
Why?
|
| Cerebral Palsy | 2 | 2018 | 52 | 1.190 |
Why?
|
| Pregnancy Complications, Cardiovascular | 3 | 2018 | 21 | 1.180 |
Why?
|
| G-Protein-Coupled Receptor Kinases | 2 | 2017 | 2 | 1.180 |
Why?
|
| Fibrinolytic Agents | 2 | 2017 | 70 | 1.130 |
Why?
|
| Labor, Obstetric | 5 | 2020 | 31 | 1.050 |
Why?
|
| Trial of Labor | 3 | 2020 | 5 | 1.050 |
Why?
|
| Premature Birth | 7 | 2021 | 39 | 1.030 |
Why?
|
| Adrenomedullin | 3 | 2014 | 4 | 1.010 |
Why?
|
| Gestational Age | 12 | 2020 | 96 | 0.990 |
Why?
|
| Young Adult | 21 | 2021 | 2402 | 0.930 |
Why?
|
| Fetal Membranes, Premature Rupture | 6 | 2019 | 10 | 0.910 |
Why?
|
| Logistic Models | 13 | 2018 | 727 | 0.900 |
Why?
|
| Trophoblasts | 2 | 2013 | 8 | 0.890 |
Why?
|
| Smoke | 2 | 2013 | 12 | 0.880 |
Why?
|
| Cervix Uteri | 3 | 2012 | 21 | 0.870 |
Why?
|
| Misoprostol | 2 | 2016 | 3 | 0.860 |
Why?
|
| Infant, Newborn | 11 | 2021 | 599 | 0.850 |
Why?
|
| Body Mass Index | 10 | 2018 | 865 | 0.840 |
Why?
|
| Ultrasonography, Prenatal | 3 | 2014 | 22 | 0.830 |
Why?
|
| Pregnancy Trimester, Third | 4 | 2020 | 17 | 0.810 |
Why?
|
| Diabetes, Gestational | 2 | 2014 | 21 | 0.800 |
Why?
|
| Patient Participation | 1 | 2020 | 62 | 0.710 |
Why?
|
| Stillbirth | 2 | 2016 | 3 | 0.660 |
Why?
|
| Seat Belts | 2 | 2015 | 17 | 0.660 |
Why?
|
| Abortion, Spontaneous | 2 | 2010 | 8 | 0.660 |
Why?
|
| Obesity, Morbid | 5 | 2018 | 55 | 0.660 |
Why?
|
| Progesterone | 2 | 2015 | 80 | 0.640 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2018 | 10 | 0.640 |
Why?
|
| Labor Presentation | 1 | 2018 | 1 | 0.640 |
Why?
|
| Magnesium | 1 | 2018 | 22 | 0.640 |
Why?
|
| Retinopathy of Prematurity | 1 | 2018 | 8 | 0.640 |
Why?
|
| Infant Mortality | 1 | 2018 | 11 | 0.630 |
Why?
|
| Retrospective Studies | 16 | 2020 | 3112 | 0.630 |
Why?
|
| Pyelonephritis | 3 | 2015 | 5 | 0.630 |
Why?
|
| Cytokines | 2 | 2016 | 243 | 0.630 |
Why?
|
| Fetal Blood | 1 | 2018 | 35 | 0.620 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2015 | 27 | 0.620 |
Why?
|
| Decidua | 2 | 2016 | 17 | 0.620 |
Why?
|
| Cell Movement | 3 | 2013 | 161 | 0.620 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2018 | 23 | 0.610 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2017 | 40 | 0.610 |
Why?
|
| Pregnancy Trimester, First | 2 | 2014 | 6 | 0.600 |
Why?
|
| Neuroprotective Agents | 1 | 2017 | 20 | 0.600 |
Why?
|
| Risk Factors | 16 | 2016 | 3537 | 0.600 |
Why?
|
| Tranexamic Acid | 1 | 2017 | 5 | 0.600 |
Why?
|
| Blood Coagulation | 1 | 2017 | 12 | 0.590 |
Why?
|
| Antifibrinolytic Agents | 1 | 2017 | 16 | 0.590 |
Why?
|
| Thrombin | 1 | 2016 | 15 | 0.590 |
Why?
|
| Heparin | 1 | 2016 | 75 | 0.570 |
Why?
|
| Pregnant Women | 1 | 2015 | 5 | 0.550 |
Why?
|
| Myometrium | 2 | 2013 | 11 | 0.550 |
Why?
|
| Continental Population Groups | 2 | 2016 | 221 | 0.540 |
Why?
|
| Uterine Inertia | 2 | 2016 | 2 | 0.540 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2016 | 145 | 0.530 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2015 | 28 | 0.530 |
Why?
|
| Health Status Disparities | 1 | 2016 | 113 | 0.530 |
Why?
|
| Heart Defects, Congenital | 1 | 2015 | 28 | 0.530 |
Why?
|
| Hospitalization | 2 | 2015 | 417 | 0.520 |
Why?
|
| Vitamin D | 1 | 2016 | 172 | 0.520 |
Why?
|
| Pregnancy in Diabetics | 1 | 2014 | 3 | 0.520 |
Why?
|
| Thrombophilia | 1 | 2014 | 6 | 0.520 |
Why?
|
| Rheumatic Diseases | 1 | 2014 | 7 | 0.520 |
Why?
|
| Maternal Age | 1 | 2014 | 8 | 0.500 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 23 | 0.490 |
Why?
|
| Multivariate Analysis | 5 | 2018 | 637 | 0.490 |
Why?
|
| Cerclage, Cervical | 2 | 2012 | 6 | 0.490 |
Why?
|
| Muscle Contraction | 3 | 2020 | 114 | 0.480 |
Why?
|
| Ethnic Groups | 1 | 2016 | 440 | 0.480 |
Why?
|
| Cardiomyopathies | 1 | 2014 | 49 | 0.470 |
Why?
|
| Smoking | 2 | 2014 | 427 | 0.460 |
Why?
|
| Inflammation | 1 | 2016 | 507 | 0.450 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 232 | 0.450 |
Why?
|
| Prevalence | 5 | 2018 | 898 | 0.450 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 1079 | 0.450 |
Why?
|
| United States | 8 | 2020 | 3632 | 0.440 |
Why?
|
| Chorion | 5 | 2015 | 8 | 0.430 |
Why?
|
| Obesity | 3 | 2017 | 1063 | 0.430 |
Why?
|
| Kidney Diseases | 1 | 2014 | 239 | 0.420 |
Why?
|
| Tobacco | 1 | 2012 | 50 | 0.410 |
Why?
|
| Uterine Hemorrhage | 1 | 2011 | 7 | 0.400 |
Why?
|
| Arrestins | 1 | 2010 | 3 | 0.390 |
Why?
|
| Labor Onset | 1 | 2010 | 1 | 0.390 |
Why?
|
| Blood Transfusion | 3 | 2020 | 64 | 0.390 |
Why?
|
| Signal Transduction | 2 | 2013 | 666 | 0.380 |
Why?
|
| Vaginal Fistula | 1 | 2010 | 2 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2017 | 641 | 0.380 |
Why?
|
| Fistula | 1 | 2010 | 11 | 0.380 |
Why?
|
| Hypertension | 2 | 2014 | 910 | 0.380 |
Why?
|
| Prospective Studies | 5 | 2020 | 2021 | 0.360 |
Why?
|
| Linear Models | 4 | 2014 | 426 | 0.350 |
Why?
|
| Case-Control Studies | 5 | 2017 | 859 | 0.350 |
Why?
|
| Adolescent | 9 | 2020 | 3255 | 0.340 |
Why?
|
| Time Factors | 6 | 2017 | 2001 | 0.330 |
Why?
|
| Hydatidiform Mole | 1 | 2008 | 4 | 0.330 |
Why?
|
| Uterine Rupture | 1 | 2008 | 1 | 0.330 |
Why?
|
| Uterine Neoplasms | 1 | 2008 | 23 | 0.320 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2008 | 16 | 0.320 |
Why?
|
| Cohort Studies | 7 | 2020 | 1688 | 0.310 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 1017 | 0.300 |
Why?
|
| Birth Weight | 2 | 2018 | 39 | 0.290 |
Why?
|
| Alkalosis | 1 | 2006 | 2 | 0.280 |
Why?
|
| Pica | 1 | 2006 | 2 | 0.280 |
Why?
|
| Sodium Bicarbonate | 1 | 2006 | 6 | 0.280 |
Why?
|
| Rhabdomyolysis | 1 | 2006 | 6 | 0.280 |
Why?
|
| Hypokalemia | 1 | 2006 | 14 | 0.280 |
Why?
|
| Abortifacient Agents, Nonsteroidal | 1 | 2005 | 1 | 0.280 |
Why?
|
| Abortion, Incomplete | 1 | 2005 | 1 | 0.280 |
Why?
|
| Cells, Cultured | 4 | 2018 | 799 | 0.270 |
Why?
|
| Extraembryonic Membranes | 3 | 2014 | 4 | 0.270 |
Why?
|
| Hydroxyprogesterones | 2 | 2015 | 3 | 0.270 |
Why?
|
| Prenatal Diagnosis | 3 | 2018 | 18 | 0.270 |
Why?
|
| Blood Component Transfusion | 3 | 2016 | 10 | 0.270 |
Why?
|
| Mice, Inbred C57BL | 3 | 2018 | 711 | 0.260 |
Why?
|
| Perineum | 2 | 2020 | 14 | 0.260 |
Why?
|
| Varicose Veins | 2 | 2018 | 6 | 0.250 |
Why?
|
| Postpartum Period | 2 | 2016 | 29 | 0.250 |
Why?
|
| Odds Ratio | 3 | 2015 | 447 | 0.250 |
Why?
|
| Matrix Metalloproteinase 9 | 2 | 2015 | 31 | 0.250 |
Why?
|
| Progestins | 2 | 2015 | 18 | 0.250 |
Why?
|
| Prenatal Care | 3 | 2017 | 46 | 0.250 |
Why?
|
| Receptors, Progesterone | 2 | 2014 | 45 | 0.240 |
Why?
|
| Male | 9 | 2020 | 17815 | 0.230 |
Why?
|
| Animals | 7 | 2020 | 7299 | 0.230 |
Why?
|
| RNA, Messenger | 3 | 2015 | 514 | 0.230 |
Why?
|
| Cell Line | 3 | 2013 | 450 | 0.230 |
Why?
|
| Gene Expression | 2 | 2016 | 332 | 0.220 |
Why?
|
| Membrane Proteins | 2 | 2014 | 256 | 0.210 |
Why?
|
| Accidents, Traffic | 2 | 2015 | 190 | 0.210 |
Why?
|
| Models, Statistical | 2 | 2020 | 163 | 0.200 |
Why?
|
| Steroids | 1 | 2021 | 36 | 0.190 |
Why?
|
| Expert Systems | 1 | 2020 | 3 | 0.190 |
Why?
|
| Birthing Centers | 1 | 2020 | 2 | 0.190 |
Why?
|
| Uterine Artery Embolization | 1 | 2020 | 4 | 0.190 |
Why?
|
| Computer Graphics | 1 | 2020 | 11 | 0.190 |
Why?
|
| Lacerations | 1 | 2020 | 7 | 0.190 |
Why?
|
| Gene Expression Regulation | 2 | 2013 | 481 | 0.190 |
Why?
|
| Wounds and Injuries | 2 | 2013 | 250 | 0.190 |
Why?
|
| Amnion | 3 | 2015 | 36 | 0.190 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2020 | 59 | 0.180 |
Why?
|
| Operating Rooms | 1 | 2020 | 32 | 0.180 |
Why?
|
| Hysterectomy | 1 | 2020 | 37 | 0.180 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 68 | 0.180 |
Why?
|
| Double-Blind Method | 2 | 2020 | 503 | 0.180 |
Why?
|
| Vaccination | 2 | 2017 | 123 | 0.170 |
Why?
|
| Vaginal Birth after Cesarean | 1 | 2019 | 2 | 0.170 |
Why?
|
| Tocolysis | 1 | 2019 | 1 | 0.170 |
Why?
|
| Tocolytic Agents | 1 | 2019 | 1 | 0.170 |
Why?
|
| Obstetric Labor, Premature | 1 | 2019 | 5 | 0.170 |
Why?
|
| Recombinant Proteins | 2 | 2020 | 248 | 0.170 |
Why?
|
| Electronic Health Records | 1 | 2020 | 118 | 0.170 |
Why?
|
| Decision Support Techniques | 1 | 2020 | 104 | 0.170 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2018 | 3 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2018 | 36 | 0.170 |
Why?
|
| Mice, Knockout | 2 | 2020 | 425 | 0.170 |
Why?
|
| Fetal Weight | 2 | 2018 | 5 | 0.170 |
Why?
|
| Genotype | 3 | 2017 | 735 | 0.170 |
Why?
|
| Abdominal Wall | 1 | 2018 | 20 | 0.170 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2018 | 47 | 0.160 |
Why?
|
| African Americans | 2 | 2016 | 1373 | 0.160 |
Why?
|
| Liver Cirrhosis | 1 | 2018 | 75 | 0.160 |
Why?
|
| Fetal Development | 1 | 2018 | 25 | 0.160 |
Why?
|
| Decision Making | 1 | 2020 | 180 | 0.160 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2018 | 104 | 0.160 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2017 | 5 | 0.160 |
Why?
|
| Epidemiologic Methods | 1 | 2017 | 24 | 0.160 |
Why?
|
| Hispanic Americans | 2 | 2016 | 904 | 0.160 |
Why?
|
| Rh-Hr Blood-Group System | 2 | 2008 | 4 | 0.160 |
Why?
|
| North Carolina | 6 | 2020 | 1423 | 0.160 |
Why?
|
| Anticonvulsants | 1 | 2018 | 63 | 0.160 |
Why?
|
| Forecasting | 1 | 2018 | 133 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2020 | 787 | 0.150 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 239 | 0.150 |
Why?
|
| Data Collection | 1 | 2017 | 163 | 0.150 |
Why?
|
| False Positive Reactions | 2 | 2008 | 25 | 0.150 |
Why?
|
| Thrombelastography | 1 | 2017 | 2 | 0.150 |
Why?
|
| Infant | 2 | 2018 | 969 | 0.150 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 73 | 0.150 |
Why?
|
| Calcium Channels | 1 | 2017 | 56 | 0.140 |
Why?
|
| Mice | 4 | 2020 | 2370 | 0.140 |
Why?
|
| Regression Analysis | 2 | 2021 | 274 | 0.140 |
Why?
|
| Respiratory Syncytial Virus, Human | 1 | 2015 | 2 | 0.140 |
Why?
|
| MAP Kinase Signaling System | 1 | 2016 | 57 | 0.140 |
Why?
|
| Muscle, Skeletal | 1 | 2020 | 494 | 0.140 |
Why?
|
| Ultrasonography | 2 | 2010 | 347 | 0.140 |
Why?
|
| Personnel Staffing and Scheduling | 1 | 2015 | 18 | 0.140 |
Why?
|
| Hydroxylation | 1 | 2015 | 4 | 0.130 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2015 | 4 | 0.130 |
Why?
|
| Microsomes | 1 | 2015 | 14 | 0.130 |
Why?
|
| Treatment Outcome | 5 | 2015 | 3101 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 41 | 0.130 |
Why?
|
| Workload | 1 | 2015 | 38 | 0.130 |
Why?
|
| Up-Regulation | 1 | 2016 | 183 | 0.130 |
Why?
|
| Cost of Illness | 1 | 2015 | 63 | 0.130 |
Why?
|
| Placenta | 1 | 2016 | 63 | 0.130 |
Why?
|
| Pregnancy, Animal | 1 | 2015 | 19 | 0.130 |
Why?
|
| Telemetry | 1 | 2015 | 27 | 0.130 |
Why?
|
| Isoenzymes | 1 | 2015 | 63 | 0.130 |
Why?
|
| Pregnancy, Multiple | 1 | 2015 | 7 | 0.130 |
Why?
|
| Medroxyprogesterone Acetate | 1 | 2015 | 89 | 0.130 |
Why?
|
| Surgical Wound Infection | 1 | 2015 | 74 | 0.130 |
Why?
|
| Cross-Sectional Studies | 2 | 2020 | 1362 | 0.130 |
Why?
|
| Protein Precursors | 1 | 2014 | 22 | 0.130 |
Why?
|
| Disease Management | 1 | 2015 | 114 | 0.130 |
Why?
|
| Diagnostic Imaging | 1 | 2015 | 88 | 0.120 |
Why?
|
| Obstetrics and Gynecology Department, Hospital | 2 | 2015 | 2 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 464 | 0.120 |
Why?
|
| Hospital Mortality | 1 | 2015 | 186 | 0.120 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2013 | 3 | 0.120 |
Why?
|
| Professional Practice | 1 | 2014 | 23 | 0.120 |
Why?
|
| Intermittent Pneumatic Compression Devices | 1 | 2013 | 2 | 0.120 |
Why?
|
| Cord Blood Stem Cell Transplantation | 1 | 2013 | 8 | 0.120 |
Why?
|
| Fibrinolysis | 1 | 2013 | 7 | 0.120 |
Why?
|
| Risk Assessment | 2 | 2020 | 1306 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 200 | 0.120 |
Why?
|
| Heart Diseases | 1 | 2014 | 99 | 0.120 |
Why?
|
| Autistic Disorder | 1 | 2013 | 6 | 0.120 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 113 | 0.120 |
Why?
|
| International Classification of Diseases | 1 | 2013 | 26 | 0.120 |
Why?
|
| Bacteria | 1 | 2014 | 45 | 0.120 |
Why?
|
| Anemia | 1 | 2013 | 55 | 0.120 |
Why?
|
| Hormone Antagonists | 1 | 2013 | 3 | 0.120 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 293 | 0.120 |
Why?
|
| Diabetes Mellitus | 2 | 2014 | 368 | 0.110 |
Why?
|
| Survival Analysis | 1 | 2014 | 440 | 0.110 |
Why?
|
| Respiration, Artificial | 1 | 2013 | 96 | 0.110 |
Why?
|
| Uterine Cervical Incompetence | 1 | 2012 | 3 | 0.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2012 | 7 | 0.110 |
Why?
|
| Anticoagulants | 1 | 2013 | 122 | 0.110 |
Why?
|
| Pregnancy Proteins | 1 | 2012 | 10 | 0.110 |
Why?
|
| Cervical Ripening | 1 | 2011 | 1 | 0.110 |
Why?
|
| Alcohol Drinking | 1 | 2014 | 244 | 0.100 |
Why?
|
| European Continental Ancestry Group | 1 | 2016 | 1131 | 0.100 |
Why?
|
| Catheterization | 1 | 2011 | 58 | 0.100 |
Why?
|
| Internship and Residency | 1 | 2015 | 283 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 466 | 0.100 |
Why?
|
| Age Factors | 1 | 2014 | 1108 | 0.100 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2012 | 103 | 0.100 |
Why?
|
| Cell Survival | 1 | 2012 | 272 | 0.100 |
Why?
|
| Stimulation, Chemical | 1 | 2010 | 12 | 0.100 |
Why?
|
| Palpation | 1 | 2010 | 9 | 0.100 |
Why?
|
| Hematocrit | 1 | 2010 | 23 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2011 | 225 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2010 | 37 | 0.100 |
Why?
|
| Pregnancy, High-Risk | 1 | 2010 | 2 | 0.100 |
Why?
|
| Area Under Curve | 1 | 2010 | 85 | 0.100 |
Why?
|
| Rh Isoimmunization | 2 | 2008 | 2 | 0.090 |
Why?
|
| Middle Aged | 4 | 2020 | 10834 | 0.090 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 109 | 0.090 |
Why?
|
| Transfection | 1 | 2010 | 192 | 0.090 |
Why?
|
| Blotting, Western | 1 | 2010 | 281 | 0.090 |
Why?
|
| Nicotine | 1 | 2012 | 157 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2011 | 285 | 0.090 |
Why?
|
| Abortion, Therapeutic | 1 | 2008 | 1 | 0.090 |
Why?
|
| Pregnancy, Ectopic | 1 | 2008 | 7 | 0.090 |
Why?
|
| Suction | 1 | 2008 | 13 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2009 | 118 | 0.080 |
Why?
|
| Chorionic Gonadotropin, beta Subunit, Human | 1 | 2008 | 2 | 0.080 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 51 | 0.080 |
Why?
|
| Cell Proliferation | 1 | 2010 | 573 | 0.080 |
Why?
|
| Glucose Tolerance Test | 1 | 2008 | 125 | 0.080 |
Why?
|
| Pregnancy Complications, Hematologic | 1 | 2007 | 2 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 22 | 0.080 |
Why?
|
| Thromboembolism | 1 | 2007 | 30 | 0.070 |
Why?
|
| Oligomenorrhea | 1 | 2006 | 1 | 0.070 |
Why?
|
| Anovulation | 1 | 2006 | 5 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 16 | 0.070 |
Why?
|
| Bariatric Surgery | 1 | 2006 | 16 | 0.070 |
Why?
|
| Dystocia | 1 | 2005 | 2 | 0.070 |
Why?
|
| Birth Injuries | 1 | 2005 | 28 | 0.070 |
Why?
|
| Brachial Plexus Neuropathies | 1 | 2005 | 36 | 0.070 |
Why?
|
| Endometrium | 1 | 2005 | 120 | 0.060 |
Why?
|
| Prognosis | 2 | 2018 | 1362 | 0.050 |
Why?
|
| Fetal Macrosomia | 2 | 2014 | 3 | 0.050 |
Why?
|
| Child | 2 | 2020 | 2219 | 0.050 |
Why?
|
| Fetal Distress | 1 | 2020 | 1 | 0.050 |
Why?
|
| Perinatal Mortality | 1 | 2020 | 1 | 0.050 |
Why?
|
| Morbidity | 1 | 2021 | 91 | 0.050 |
Why?
|
| Infant, Small for Gestational Age | 1 | 2020 | 4 | 0.050 |
Why?
|
| Pregnancy Trimester, Second | 1 | 2020 | 13 | 0.050 |
Why?
|
| ROC Curve | 1 | 2021 | 149 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2020 | 21 | 0.050 |
Why?
|
| User-Computer Interface | 1 | 2020 | 34 | 0.050 |
Why?
|
| Obstetrics | 1 | 2020 | 16 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 532 | 0.050 |
Why?
|
| Triage | 1 | 2020 | 65 | 0.040 |
Why?
|
| Clenbuterol | 1 | 2018 | 2 | 0.040 |
Why?
|
| Hypertrophy | 1 | 2018 | 26 | 0.040 |
Why?
|
| Phenotype | 1 | 2021 | 629 | 0.040 |
Why?
|
| Calcium Channel Blockers | 1 | 2019 | 49 | 0.040 |
Why?
|
| Models, Econometric | 1 | 2018 | 7 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2019 | 50 | 0.040 |
Why?
|
| Calcium Signaling | 1 | 2018 | 40 | 0.040 |
Why?
|
| Polysomnography | 1 | 2018 | 33 | 0.040 |
Why?
|
| Growth Charts | 1 | 2018 | 3 | 0.040 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2019 | 71 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 159 | 0.040 |
Why?
|
| Muscle Strength | 1 | 2018 | 139 | 0.040 |
Why?
|
| Reference Values | 1 | 2018 | 224 | 0.040 |
Why?
|
| Severity of Illness Index | 2 | 2013 | 863 | 0.040 |
Why?
|
| Blood Coagulation Disorders | 1 | 2016 | 9 | 0.040 |
Why?
|
| DNA | 2 | 2008 | 204 | 0.030 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2015 | 9 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2018 | 726 | 0.030 |
Why?
|
| Work Schedule Tolerance | 1 | 2015 | 9 | 0.030 |
Why?
|
| Genital Neoplasms, Female | 1 | 2015 | 15 | 0.030 |
Why?
|
| Iatrogenic Disease | 1 | 2015 | 14 | 0.030 |
Why?
|
| Urologic Neoplasms | 1 | 2015 | 11 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2013 | 2109 | 0.030 |
Why?
|
| Neuromuscular Diseases | 1 | 2015 | 13 | 0.030 |
Why?
|
| Pressure | 1 | 2015 | 54 | 0.030 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 38 | 0.030 |
Why?
|
| Intestinal Diseases | 1 | 2015 | 18 | 0.030 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 83 | 0.030 |
Why?
|
| Pneumonia | 1 | 2015 | 61 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2015 | 116 | 0.030 |
Why?
|
| Fetal Growth Retardation | 1 | 2014 | 17 | 0.030 |
Why?
|
| Mice, Transgenic | 1 | 2015 | 249 | 0.030 |
Why?
|
| Blood Coagulation Disorders, Inherited | 1 | 2014 | 1 | 0.030 |
Why?
|
| Expert Testimony | 1 | 2014 | 10 | 0.030 |
Why?
|
| Hemostatics | 1 | 2014 | 12 | 0.030 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 17 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 2 | 1 | 2013 | 1 | 0.030 |
Why?
|
| Urokinase-Type Plasminogen Activator | 1 | 2013 | 3 | 0.030 |
Why?
|
| Least-Squares Analysis | 1 | 2014 | 29 | 0.030 |
Why?
|
| Antithrombin III | 1 | 2013 | 4 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2014 | 37 | 0.030 |
Why?
|
| Hypothermia, Induced | 1 | 2013 | 16 | 0.030 |
Why?
|
| Developmental Disabilities | 1 | 2013 | 12 | 0.030 |
Why?
|
| Peptide Hydrolases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Birth Certificates | 1 | 2013 | 4 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2013 | 78 | 0.030 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2013 | 46 | 0.030 |
Why?
|
| Parity | 1 | 2013 | 12 | 0.030 |
Why?
|
| Infant, Premature | 1 | 2013 | 62 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 493 | 0.030 |
Why?
|
| Abruptio Placentae | 1 | 2013 | 3 | 0.030 |
Why?
|
| Fetal Death | 1 | 2013 | 6 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2013 | 126 | 0.030 |
Why?
|
| Influenza, Human | 1 | 2015 | 122 | 0.030 |
Why?
|
| Air Bags | 1 | 2013 | 14 | 0.030 |
Why?
|
| Motor Vehicles | 1 | 2013 | 22 | 0.030 |
Why?
|
| Schools | 1 | 2013 | 64 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2013 | 263 | 0.030 |
Why?
|
| Medical Records | 1 | 2013 | 68 | 0.030 |
Why?
|
| Risk | 1 | 2013 | 289 | 0.030 |
Why?
|
| Clinical Competence | 1 | 2015 | 307 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 525 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2013 | 469 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2014 | 519 | 0.030 |
Why?
|
| Ampicillin | 1 | 2011 | 3 | 0.030 |
Why?
|
| Emergencies | 1 | 2012 | 45 | 0.030 |
Why?
|
| Azithromycin | 1 | 2011 | 14 | 0.030 |
Why?
|
| Sex Factors | 1 | 2013 | 631 | 0.030 |
Why?
|
| Registries | 1 | 2013 | 278 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2011 | 159 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 374 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 486 | 0.020 |
Why?
|
| Mothers | 1 | 2011 | 79 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2013 | 1167 | 0.020 |
Why?
|
| Apgar Score | 1 | 2009 | 5 | 0.020 |
Why?
|
| New Jersey | 1 | 2009 | 10 | 0.020 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2009 | 27 | 0.020 |
Why?
|
| Oocyte Retrieval | 1 | 2008 | 2 | 0.020 |
Why?
|
| Sperm Injections, Intracytoplasmic | 1 | 2008 | 5 | 0.020 |
Why?
|
| Live Birth | 1 | 2008 | 5 | 0.020 |
Why?
|
| Hemostasis, Surgical | 1 | 2008 | 13 | 0.020 |
Why?
|
| Ovulation Induction | 1 | 2008 | 8 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2008 | 17 | 0.020 |
Why?
|
| Embryo Transfer | 1 | 2008 | 9 | 0.020 |
Why?
|
| Fertilization in Vitro | 1 | 2008 | 20 | 0.020 |
Why?
|
| Balloon Occlusion | 1 | 2008 | 29 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1119 | 0.020 |
Why?
|
| Genetic Markers | 1 | 2008 | 122 | 0.020 |
Why?
|
| Pregnancy Trimesters | 1 | 2006 | 3 | 0.020 |
Why?
|
| Recurrence | 1 | 2007 | 235 | 0.020 |
Why?
|
| Diagnostic Errors | 1 | 2006 | 42 | 0.020 |
Why?
|
| Health Surveys | 1 | 2006 | 191 | 0.020 |
Why?
|
| Episiotomy | 1 | 2005 | 2 | 0.020 |
Why?
|
| Obstetrical Forceps | 1 | 2005 | 3 | 0.020 |
Why?
|
| Vacuum Extraction, Obstetrical | 1 | 2005 | 4 | 0.020 |
Why?
|
| Maryland | 1 | 2005 | 26 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2005 | 24 | 0.020 |
Why?
|
| Weight Loss | 1 | 2006 | 413 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 1219 | 0.010 |
Why?
|